AcelRx to Host Second Quarter 2023 Financial Results Call and Webcast on August 10, 2023

Rhea-AI Summary

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) will release its second quarter 2023 financial results after market close on August 10, 2023. The company will host a live webcast and conference call at 4:30 p.m. EDT/1:30 p.m. PDT to discuss the results and provide a business update.

HAYWARD, Calif., July 27, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2023 financial results after market close on Thursday, August 10, 2023, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.  

Webcast Information

The webcast can be accessed here or by visiting the Investors section of the Company's website at www.acelrx.com and clicking on the webcast link within News & Events/Upcoming Events section.  The webcast will include a slide presentation and a replay will be available on the AcelRx website for 90 days following the event.

Conference Call Information

Investors who wish to participate in the conference call may do so by dialing 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 (toll applies) for international callers. The conference ID is 10181172.

About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. AcelRx's lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. AcelRx is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, with an expected NDA filing in 2023, and PFS-02, a pre-filled phenylephrine syringe with an expected NDA filing in 2024. This release is intended for investors only. For additional information about AcelRx, please visit www.acelrx.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-second-quarter-2023-financial-results-call-and-webcast-on-august-10-2023-301887209.html

SOURCE AcelRx Pharmaceuticals, Inc.

FAQ

When will AcelRx Pharmaceuticals release its second quarter 2023 financial results?

AcelRx Pharmaceuticals will release its second quarter 2023 financial results after market close on Thursday, August 10, 2023.

What will AcelRx Pharmaceuticals discuss during the webcast and conference call?

AcelRx Pharmaceuticals will discuss the second quarter 2023 financial results and provide an update on the company's business.

How can I access the webcast?

The webcast can be accessed on the AcelRx Pharmaceuticals website at www.acelrx.com by clicking on the webcast link within the News & Events/Upcoming Events section.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available on the AcelRx Pharmaceuticals website for 90 days following the event.

How can I participate in the conference call?

To participate in the conference call, dial 1-866-361-2335 for domestic callers, 1-855-669-9657 for Canadian callers, or 1-412-902-4204 (toll applies) for international callers. The conference ID is 10181172.